Novocure (NVCR) Tops Q2 EPS by 20c; offers guidance

Novocure (NASDAQ: NVCR) reported Q2 EPS of ($0.13), $0.20 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $183.6 million versus the consensus estimate of $172.72 million.

GUIDANCE:

Novocure sees FY2026 revenue of $710-725 million, versus the consensus of $708.7 million.

For earnings history and earnings-related data on Novocure (NVCR) click here.

You May Also Be Interested In

• Freedom Broker Upgrades Core Scientific Inc. (CORZ) to Buy
• Jones Lang LaSalle (JLL) PT Raised to $500 at Raymond James
• Piper Sandler Companies (PIPR) Tops Q2 EPS by 16c